EWTX vs. SUPN, AVDL, TARO, HRMY, SDGR, ZLAB, CPRX, SNDX, AGIO, and GPCR
Should you be buying Edgewise Therapeutics stock or one of its competitors? The main competitors of Edgewise Therapeutics include Supernus Pharmaceuticals (SUPN), Avadel Pharmaceuticals (AVDL), Taro Pharmaceutical Industries (TARO), Harmony Biosciences (HRMY), Schrödinger (SDGR), Zai Lab (ZLAB), Catalyst Pharmaceuticals (CPRX), Syndax Pharmaceuticals (SNDX), Agios Pharmaceuticals (AGIO), and Structure Therapeutics (GPCR). These companies are all part of the "pharmaceutical preparations" industry.
Supernus Pharmaceuticals (NASDAQ:SUPN) and Edgewise Therapeutics (NASDAQ:EWTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.
In the previous week, Edgewise Therapeutics had 4 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 10 mentions for Edgewise Therapeutics and 6 mentions for Supernus Pharmaceuticals. Edgewise Therapeutics' average media sentiment score of 0.24 beat Supernus Pharmaceuticals' score of -0.37 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media.
Supernus Pharmaceuticals has higher revenue and earnings than Edgewise Therapeutics.
Supernus Pharmaceuticals presently has a consensus price target of $41.00, suggesting a potential upside of 32.99%. Edgewise Therapeutics has a consensus price target of $31.20, suggesting a potential upside of 59.84%. Given Supernus Pharmaceuticals' higher probable upside, analysts clearly believe Edgewise Therapeutics is more favorable than Supernus Pharmaceuticals.
Supernus Pharmaceuticals has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500. Comparatively, Edgewise Therapeutics has a beta of 0.15, suggesting that its stock price is 85% less volatile than the S&P 500.
Supernus Pharmaceuticals received 451 more outperform votes than Edgewise Therapeutics when rated by MarketBeat users. Likewise, 73.25% of users gave Supernus Pharmaceuticals an outperform vote while only 62.50% of users gave Edgewise Therapeutics an outperform vote.
Supernus Pharmaceuticals has a net margin of 0.22% compared to Supernus Pharmaceuticals' net margin of 0.00%. Edgewise Therapeutics' return on equity of 0.14% beat Supernus Pharmaceuticals' return on equity.
Summary
Supernus Pharmaceuticals beats Edgewise Therapeutics on 9 of the 12 factors compared between the two stocks.
Get Edgewise Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for EWTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EWTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Edgewise Therapeutics Competitors List
Related Companies and Tools
